Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Apr, 2019 | Pages:
165 | Publisher: Grand View Research
Industry: Biotechnology | Report Format: Electronic (PDF)
The global gene therapy market size is expected to reach USD 5.55 billion by 2026, growing at a CAGR of 33.9% over the forecast period, according to a new report by Grand View Research, Inc. Gene therapy is being developed with an aim to identify and cure rare conditions, diseases that have limited treatment options and that need lifelong medication to keep the symptoms in check. For instance, metabolic disorders like lysosomal diseases need constant medical attention with the medication available now, however, gene therapy might become a one-time cure to such diseases. There are a number of molecules under development due to intense competition. This factor is projected to be the key factor propelling the market growth. In early 2018, there were more than 950 molecules in the pipeline with various regulatory bodies in various clinical phases. However, around 76% of the molecules are in the developmental or preclinical stages and are expected to be available by the late 2020s. Larger pharma/biotech companies are entering into the market by either acquiring the licensing/manufacturing rights from smaller companies that are solely dedicated to gene therapy research or by building a dedicated research portfolio with investments and clinical trials. These factors are also expected to boost the market growth over the next two decades. Most of the manufacturers are also developing molecules that can help cure various cancers. Growing prevalence of different types of cancer emphasizes the need for the development of robust treatment options. Ongoing developments in cancer gene studies have provided significant information about cancer-related molecular signatures, which in turn, is expected to support the ongoing clinical trials for cancer therapeutics. Further key findings from the study suggest: • 7 gene therapy molecules have been approved by various regulatory bodies. In 2018, the FDA approved 3 molecules • Lentivirus is being used as viral vector of choice for 2 of the 3 molecules approved by the FDA • U.S. and Europe are expected to occupy the largest market shares over the forecast period owing to gene therapy molecules being marketed in these regions • Europe is set to grow at a fast pace due to the growing pipeline molecules and a number of companies competing in the regional market • Key companies in the market are Novartis AG, Gilead Sciences, Inc.; UniQure N.V.; Spark Therapeutics LLC; Bluebird Bio; Juno Therapeutics; GlaxoSmithKline PLC; Celgene Corporation; Shire PLC; Sangamo Biosciences, Inc.; Dimension Therapeutics, Inc.; Voyager Therapeutics, Inc.; Human Stem Cell Institute; Chiesi Farmaceutici S.p.A.; and Bristol-Myers Squibb Company
Table of Contents
Chapter 1. Research Methodology
1.1 Market segmentation & scope
1.2 Market definition
1.3 Information procurement
1.3.1 Purchased database
1.3.2 GVR’s internal database
1.3.3 Secondary sources & third party perspectives
1.3.4 Primary research
1.4 Information analysis
1.4.1 Data analysis models
1.5 Market formulation & data visualization
1.6 Data validation & publishing
Chapter 2. Executive Summary
2.1 Market Outlook
2.2 Segment Outlook
2.3 Competitive Insights
Chapter 3. Gene Therapy Market Variables, Trends & Scope
3.1 Market Lineage Outlook
3.1.1 Related/ancillary market outlook
3.2 Penetration & Growth Prospect Mapping
3.3 Product Pipeline Analysis, by Stage
3.4 Industry Analysis
3.4.1 Cost structure analysis
3.4.2 User perspective analysis
3.4.2.1 Consumer behavior analysis
3.4.2.2 Market influencer analysis
3.4.3 Procedure cost analysis
3.5 Technology Overview
3.5.1 Technology timeline
3.6 Regulatory Framework
3.6.1 Reimbursement framework
3.6.2 Standards & compliance
3.6.3 Safety
3.7 Market Dynamics
3.7.1 Market driver analysis
3.7.1.1 Robust pipeline in development
3.7.1.2 Introduction of technological advancements
3.7.1.3 Increasing investment from the companies and partnerships
3.7.1.4 Growing prevalence of target diseases and increased demand for innovative medicine
3.7.2 Market restrain analysis
3.7.2.1 Presence of ambiguous regulatory framework
3.7.2.2 High prices of gene therapy medicines
3.7.3 Industry challenges
3.7.3.1 High cost of development
3.7.3.2 Vector availability
3.8 Gene Therapy Market Analysis Tools
3.8.1 Industry Analysis - Porter's
3.8.1.1 Supplier power - High
3.8.1.2 Buyer power - Medium
3.8.1.3 Substitution threat - High
3.8.1.4 New entrants threat - Medium
3.8.2 PESTEL analysis
3.8.2.1 Political Landscape
3.8.2.2 Environmental Landscape
3.8.2.3 Social Landscape
3.8.2.4 Technology Landscape
3.8.2.5 Legal Landscape
3.8.3 Major Deals & Strategic Alliances Analysis
3.8.3.1. Joint Ventures
3.8.3.2. Mergers & Acquisitions
3.8.3.3. Licensing & Partnership
3.8.3.4. Technology Collaborations
3.8.3.5. Strategic Divestments
3.8.4 Market entry strategies
3.8.5 Case studies
Chapter 4. Gene Therapy Market - Competitive Analysis
4.1. Recent developments & impact analysis, by key market participants
4.2. Company/Competition Categorization (Key innovators, Market leaders, Emerging players)
4.3. Vendor Landscape
4.3.1. List of key distributors and channel partners
4.3.2. Key customers
4.3.3. Key company market share analysis, 2018
4.4. Public Companies
4.4.1. Company market position analysis
4.4.2. Company Market Share/Ranking, by region
4.4.3. Competitive Dashboard Analysis
4.4.3.1. Market Differentiators
4.4.3.2. Synergy Analysis: Major Deals & Strategic Alliances
4.5. Private Companies
4.5.1. List of key emerging companies’ /technology disruptors/innovators
4.5.2. Funding Outlook (Optional)
4.5.3. Regional network map
4.5.4. Company market position analysis (geographic presence, product portfolio, key alliance, industry experience)
4.5.5. Supplier Ranking
Chapter 5. Gene Therapy Market Outlook, Estimates & Trend Analysis
5.1 Definitions & Scope
5.2 Indication Market Share Analysis, 2018 to 2026
5.3 Segment Dashboard
5.4 Gene Therapy Market, by Indication, 2014 to 2026
5.5 Market Size & Forecasts and Trend Analysis, 2014 to 2026
5.5.1 Acute Lymphoblastic Leukemia (ALL)
5.5.2 Inherited Retinal Disease
5.5.3 Large B-cell Lymphoma
5.5.4 ADA-SCID
5.5.5 Melanoma (lesions)
5.5.6 Beta-thalassemia Major/SCD
5.5.7 Head & Neck Squamous Cell Carcinoma
5.5.8 Peripheral Arterial Disease
5.6 Gene Therapy Market Share by Vector, 2014 to 2026
5.7 Market Size & Forecasts and Trend Analysis, 2014 to 2026
5.7.1 Lentivirus
5.7.2 Adeno-associated Virus
5.7.3 Retrovirus & Gamma Retrovirus
5.7.4 Modified Herpes Simplex Virus
5.7.5 Adenovirus
5.7.6 Vaccinia Virus
5.7.7 Baculovirus (Bacmid)
5.7.8 Non-viral Plasmid Vector
5.7.9 Injection of naked DNA
5.7.10 Lipofection
Chapter 6. Gene Therapy Market: Regional Estimates & Trend analysis, by Indication & Vector Type
6.1 Regional Market Snapshot
6.2 Regional Market Share and Leading Players, 2018
6.2.1 North America
6.2.2 Europe
6.2.3 Asia Pacific
6.2.4 Rest of World
6.3 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
6.3.1. North America
6.3.2. Europe
6.3.3. Asia Pacific
6.3.4. Rest of World
6.4 Market Size, & Forecasts, and Trend Analysis, 2018 to 2026:
6.4.1. North America
6.4.2. Europe
6.4.3. Asia Pacific
6.4.4. Rest of World
Chapter 7. Company Profiles
7.1 Company Profiles
7.1.1 UniQure N.V
7.1.1.1 Company overview
7.1.1.2 Financial performance
7.1.1.3 Product benchmarking
7.1.1.4 Strategic initiatives
7.1.2 Spark Therapeutics LLC
7.1.2.1 Company overview
7.1.2.2 Financial performance
7.1.2.3 Product benchmarking
7.1.2.4 Strategic initiatives
7.1.3 Bluebird Bio
7.1.3.1 Company overview
7.1.3.2 Financial performance
7.1.3.3 Product benchmarking
7.1.3.4 Strategic initiatives
7.1.4 Celgene Corporation
7.1.4.1 Company overview
7.1.4.2 Financial Performance
7.1.4.3 Product benchmarking
7.1.4.4 Strategic initiatives
7.1.5 GlaxoSmithKline plc.
7.1.5.1 Company overview
7.1.5.2 Financial performance
7.1.5.3 Product benchmarking
7.1.5.4 Strategic initiatives
7.1.6 Shire Plc.
7.1.6.1 Company overview
7.1.6.2 Financial performance
7.1.6.3 Product benchmarking
7.1.6.4 Strategic initiatives
7.1.7 Cellectis
7.1.7.1 Company overview
7.1.7.2 Financial performance
7.1.7.3 Product benchmarking
7.1.7.4 Strategic initiatives
7.1.8 Sangamo Biosciences Inc.,
7.1.8.1 Company overview
7.1.8.2 Financial performance
7.1.8.3 Product benchmarking
7.1.8.4 Strategic initiatives
7.1.9 ReGenX Bio. Inc.,
7.1.9.1 Company overview
7.1.9.2 Financial performance
7.1.9.3 Product benchmarking
7.1.9.4 Strategic initiatives
7.1.10 Oxford Biomedica Plc.
7.1.10.1 Company overview
7.1.10.2 Financial performance
7.1.10.3 Product benchmarking
7.1.10.4 Strategic initiatives
7.1.11 Voyager Therapeutics
7.1.11.1 Company overview
7.1.11.2 Financial performance
7.1.11.3 Product benchmarking
7.1.11.4 Strategic initiatives
7.1.12 Human Stem Cells Institute
7.1.12.1 Company overview
7.1.12.2 Financial performance
7.1.12.3 Product benchmarking
7.1.12.4 Strategic initiatives
7.1.13 Dimension Therapeutics Inc.
7.1.13.1 Company overview
7.1.13.2 Financial performance
7.1.13.3 Product benchmarking
7.1.13.4 Strategic initiatives
7.1.14 Bristol Myers Squibb
7.1.14.1 Company overview
7.1.14.2 Financial performance
7.1.14.3 Product benchmarking
7.1.14.4 Strategic initiatives
7.1.15 Sanofi Genzyme
7.1.15.1 Company overview
7.1.15.2 Financial performance
7.1.15.3 Product benchmarking
7.1.15.4 Strategic initiatives
7.1.16 Applied Genetic Technologies Corporation
7.1.16.1 Company overview
7.1.16.2 Financial performance
7.1.16.3 Product benchmarking
7.1.16.4 Strategic initiatives
7.1.17 Chiesi Farmaceutici S.p.A
7.1.17.1 Company overview
7.1.17.2 Financial performance
7.1.17.3 Product benchmarking
7.1.17.4 Strategic initiatives
7.1.18 Benitec BioPharma
7.1.18.1 Company overview
7.1.18.2 Financial performance
7.1.18.3 Product benchmarking
7.1.18.4 Strategic initiatives
7.1.19 Sibiono GeneTech Co. Ltd
7.1.19.1 Company overview
7.1.19.2 Financial performance
7.1.19.3 Product benchmarking
7.1.20 Shanghai Sunway Biotech Co. Ltd
7.1.20.1 Company overview
7.1.20.2 Financial performance
7.1.21 GenSight Biologics S.A
7.1.21.1 Company overview
7.1.21.2 Financial performance
7.1.21.3 Product benchmarking
7.1.21.4 Strategic initiatives
7.1.22 Transgene S.A
7.1.22.1 Company overview
7.1.22.2 Financial performance
7.1.22.3 Product benchmarking
7.1.23 Epeius Biotechnologies Corp
7.1.23.1 Company overview
7.1.23.2 Financial performance
7.1.23.3 Product benchmarking
7.1.24 Calimmune Inc.
7.1.24.1 Company overview
7.1.24.2 Financial performance
7.1.24.3 Product benchmarking
7.1.25 American Gene Technologies
7.1.25.1 Company overview
7.1.25.2 Financial performance
7.1.26 Juno Therapeutics, Inc.
7.1.26.1 Company overview
7.1.26.2 Financial performance
7.1.26.3 Product benchmarking
7.1.26.4 Strategic initiatives
7.1.27 BioMarin Pharmaceuticals, Inc.
7.1.27.1 Company overview
7.1.27.2 Financial performance
7.1.27.3 Product benchmarking
7.1.28 TaxusCardium Pharmaceuticals Inc.
7.1.28.1 Company overview
7.1.28.2 Financial performance
7.1.28.3 Product benchmarking
7.1.28.4 Strategic initiatives
7.1.29 Novartis AG
7.1.29.1 Company overview
7.1.29.2 Financial performance
7.1.29.3 Product benchmarking
7.1.29.4 Strategic initiatives
7.1.30 Orchard Therapeutics
7.1.30.1 Company overview
7.1.30.2 Financial performance
7.1.30.3 Product benchmarking
7.1.30.4 Strategic initiatives
7.1.31 Gilead Sciences Inc.
7.1.31.1 Company overview
7.1.31.2 Financial performance
7.1.31.3 Product benchmarking
7.1.31.4 Strategic initiatives
7.1.32 WuXi PharmaTec.
7.1.32.1 Company overview
7.1.32.2 Financial performance
7.1.32.3 Product benchmarking
7.1.32.4 Strategic initiatives
7.1.33 Ypokesi
7.1.33.1 Company overview
7.1.33.2 Financial performance
7.1.33.3 Product benchmarking
7.1.33.4 Strategic initiatives
7.1.34 Lonza
7.1.34.1 Company overview
7.1.34.2 Financial performance
7.1.34.3 Product benchmarking
7.1.34.4 Strategic initiatives
7.1.35 CellforCure
7.1.35.1 Company overview
7.1.35.2 Financial performance
7.1.35.3 Product benchmarking
7.1.35.4 Strategic initiatives
7.1.36 Cevec
7.1.36.1 Company overview
7.1.36.2 Financial performance
7.1.36.3 Product benchmarking
7.1.36.4 Strategic initiatives
7.1.37 Novasep
7.1.37.1 Company overview
7.1.37.2 Financial performance
7.1.37.3 Product benchmarking
7.1.37.4 Strategic initiatives
7.1.38 Brammer Bio
7.1.38.1 Company overview
7.1.38.2 Financial performance
7.1.38.3 Product benchmarking
7.1.38.4 Strategic initiatives
7.2 List of Companies
List of Tables TABLE 1 North America gene therapy market, by indication type, 2014 - 2026 (USD Million) TABLE 2 North America gene therapy market, by vector type, 2014 - 2026 (USD Million) TABLE 3 U.S. gene therapy market, by indication type, 2014 - 2026 (USD Million) TABLE 4 U.S. gene therapy market, by vector type, 2014 - 2026 (USD Million) TABLE 5 Europe gene therapy market, by indication type, 2014 - 2026 (USD Million) TABLE 6 Europe gene therapy market, by vector type, 2014 - 2026 (USD Million) TABLE 7 Asia Pacific gene therapy market, by indication type, 2014 - 2026 (USD Million) TABLE 8 Asia Pacific gene therapy market, by vector type, 2014 - 2026 (USD Million) TABLE 9 Rest of the World gene therapy market, by indication type, 2014 - 2026 (USD Million) TABLE 10 Rest of the World gene therapy market, by vector type, 2014 - 2026 (USD Million) List of Figures FIG. 1 Market summary FIG. 2 Market trends & outlook FIG. 3 Market segmentation & scope FIG. 4 Market driver relevance analysis (current & future impact) FIG. 5 Market restrain relevance analysis (current & future impact) FIG. 6 Penetration & growth prospect mapping FIG. 7 SWOT analysis, by factor (political & legal, economic and technological) FIG. 8 Porter’s five forces analysis FIG. 9 Gene therapy market indication type outlook key takeaways FIG. 10 Gene therapy market: Indication type movement analysis FIG. 11 Acute lymphoblastic leukemia (ALL) market, 2014 - 2026 (USD Million) FIG. 12 Inherited retinal disease market, 2014 - 2026 (USD Million) FIG. 13 Large b-cell lymphoma market, 2014 - 2026 (USD Million) FIG. 14 ADA-SCID market, 2014 - 2026 (USD Million) FIG. 15 Melanoma (lesions) market, 2014 - 2026 (USD Million) FIG. 16 Beta-thalassemia major/SCD market, 2014 - 2026 (USD Million) FIG. 17 Head & neck squamous cell carcinoma market, 2014 - 2026 (USD Million) FIG. 18 Peripheral arterial disease market, 2014 - 2026 (USD Million) FIG. 19 Gene therapy market vector type outlook: Key takeaways FIG. 20 Gene therapy market: vector type market: Movement analysis FIG. 21 Lentivirus market, 2014 - 2026 (USD Million) FIG. 22 Adeno-associated virus market, 2014 - 2026 (USD Million) FIG. 23 Retrovirus & gamma retrovirus market, 2014 - 2026 (USD Million) FIG. 24 Modified herpes implex virus market, 2014 - 2026 (USD Million) FIG. 25 Adenovirus market, 2014 - 2026 (USD Million) FIG. 26 Vaccinia virus market, 2014 - 2026 (USD Million) FIG. 27 Baculovirus market, 2014 - 2026 (USD Million) FIG. 28 Non-viral plasmid vector market, 2014 - 2026 (USD Million) FIG. 29 Injection of naked DNA market, 2014 - 2026 (USD Million) FIG. 30 Lipofection market, 2014 - 2026 (USD Million) FIG. 31 Regional market place: Key takeaways FIG. 32 Regional outlook, 2018 & 2026 FIG. 33 Strategy framework FIG. 34 Participant categorization
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
